A5037698990- Renal Transplantation Outcomes and Treatments
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Pharmaceutical Practices and Patient Outcomes
- Biosimilars and Bioanalytical Methods
- Neurological Complications and Syndromes
- Organ Transplantation Techniques and Outcomes
- Pharmacological Effects and Toxicity Studies
- HIV/AIDS drug development and treatment
- Cytomegalovirus and herpesvirus research
- Antibiotic Use and Resistance
- Pneumocystis jirovecii pneumonia detection and treatment
- Pregnancy and Medication Impact
- Transplantation: Methods and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Herpesvirus Infections and Treatments
- Medication Adherence and Compliance
- COVID-19 Clinical Research Studies
- Organ Donation and Transplantation
- Virus-based gene therapy research
- Adenosine and Purinergic Signaling
- Autoimmune Neurological Disorders and Treatments
- Bacterial Identification and Susceptibility Testing
- Gout, Hyperuricemia, Uric Acid
- Medical Device Sterilization and Disinfection
Mayo Clinic in Arizona
2019-2025
Mayo Clinic
2020-2022
Yale New Haven Health System
2015-2020
Yale New Haven Hospital
2003-2018
The University of Texas MD Anderson Cancer Center
2015
Yale University
2015
Memorial Sloan Kettering Cancer Center
2015
Yale Cancer Center
2013
Brigham and Women's Hospital
2013
Harvard University
2013
Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2022 the United States, with a focus on nonfederal hospital clinic sectors. Methods Historical were assessed by examining data purchases from manufacturers using IQVIA National Sales Perspectives database. Factors hospitals clinics reviewed—including new approvals, patent expirations, potential policies or legislation....
Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2023 the United States, with a focus on nonfederal hospital clinic sectors. Methods Historical were assessed by examining data purchases from manufacturers using IQVIA National Sales Perspectives database. Factors hospitals clinics reviewed, including new approvals, patent expirations, potential policies or legislation....
To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2024 the United States, with a focus on nonfederal hospital clinic sectors.
Background. The first generic tacrolimus product gained Food and Drug Administration approval in August 2009. This prospective, observational trial sought to determine the need for dose titrations measure drug cost savings on conversion tacrolimus. Methods. Transplant recipients stable doses were converted from brand a mg:mg basis. Data collected at time of (study arm) point exactly 6 months before (control all subjects. Results. Seventy conversions four centers are reported. Subjects mean...
Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2021 the United States, with a focus on nonfederal hospital clinic sectors. Methods Historical were assessed by examining data purchases from manufacturers using IQVIA National Sales Perspectives database. Factors hospitals clinics reviewed—including new approvals, patent expirations, potential policies or legislation....
Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2020 the United States, with a focus on nonfederal hospital clinic sectors. Methods Historical were assessed by examining data purchases from manufacturers using IQVIA National Sales Perspectives database. Factors hospitals clinics reviewed, including new approvals, patent expirations, potential policies or legislation....
Abstract Purpose: The 2024 ASHP Pharmacy Forecast identifies and contextualizes emerging issues trends that will influence healthcare, health systems, the pharmacy profession provides recommendations to inform long-term strategic planning should prompt action by pharmacists health-system leaders. Methods: Drawing on “wisdom of crowds” concept, a survey was constructed with 6 general themes, each 9 focused statements seventh theme preparedness (58 items in total). size representation within...
In Brief Background Despite proven efficacy of prolonged cytomegalovirus (CMV) prophylaxis using valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost savings. This multicenter, retrospective study compared the safety 6 months low-dose versus high-dose in high-risk, donor-positive/recipient-negative, renal transplant recipients (RTR). Methods Two hundred thirty-seven high-risk RTR (low-dose group = [n 130]; s7]) were evaluated for 1-year CMV disease...
Abstract Purpose Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, projections made for drug spending in 2019 nonfederal hospitals, clinics, overall (all sectors). Methods Drug expenditure data through calendar year 2018 were obtained from the IQVIA National Sales Perspectives database analyzed. New approvals, patent expirations, other that may hospitals clinics also reviewed. Expenditure sectors) a combination of quantitative analyses expert...
Abstract Objective: To better understand clinicians’ rationale for ordering testing C. difficile infection (CDI) patients receiving laxatives and the impact of implementation a clinical decision support (CDS) intervention. Design: A mixed-methods, case series was performed from March 2, 2017 to December 31, 2018. Setting: Yale New Haven Hospital, 1,541 bed tertiary academic medical center. Participants: Hospitalized ≥ 18 years old, clinicians who were alerted by CDS. Intervention: CDS...
Abstract Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon possible after acceptance. Accepted have been peer-reviewed and copyedited, but are posted before technical formatting author proofing. These not final version record will be replaced with article (formatted per style proofed by authors) at a later time. Purpose To report historical patterns pharmaceutical expenditures, identify factors that may influence future spending,...
Abstract Background The cytomegalovirus ( CMV ) donor‐positive/recipient‐positive (D+/R+) population is the largest proportion of renal transplant recipients RTR ). Guidelines for prevention in intermediate‐risk D+/R+ include prophylaxis with valganciclovir VGCV 900 mg/day 3 months. This study first head‐to‐head analysis, to our knowledge, comparing efficacy and safety 450 vs months . Methods A multicenter, retrospective analysis evaluated 478 adult between January 2008 October 2011. Study...
The implementation and outcomes of a pharmacist career ladder program (PCLP) at tertiary care, academic medical center are described.A PCLP was developed Yale-New Haven Hospital to guide development, motivate staff perform beyond their daily tasks responsibilities, recognize retain high performers through professional advancement. advancement criteria include specific requirements for excellence in five categories: level training experience, pharmacy practice, drug information, education...
Benefits of belatacept-based immunosuppressive regimens in human immunodeficiency virus (HIV)-positive renal transplant recipients include avoidance drug interactions between calcineurin inhibitors and highly active antiretroviral agents decreased likelihood or severity nonimmune toxicities such as new-onset diabetes after transplant, hyperlipidemia hypertension. We report a successful case de novo belatacept at >18 mo from an HIV-positive black man aged 50 years who received his first...